ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma & Antonio “Tony” Pera to Board of Direct...
August 06 2020 - 6:45AM
Business Wire
Additions reflect ANI’s commitment to
broaden pharmaceutical industry experience on Board
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq:ANIP)
today announced the appointments of Jeanne Thoma, President and
Chief Executive Officer of SPI Pharma, Inc. and Antonio (“Tony”)
Pera, former President of Par Pharmaceutical to the ANI
Pharmaceuticals Board of Directors. These appointments are
effective immediately and increase ANI’s Board of Directors to
seven members, including Nikhil Lalwani, who will join the Board
next month when he starts as President and CEO of the Company on
September 8, 2020.
These appointments represent a continuation of ANI’s efforts to
broaden the scope of industry experience on the Board of Directors,
as well as to bring forth more unique perspectives through enhanced
diversity.
“As we pursue our dual goals of expanding the pharmaceutical
industry expertise and broadening the diversity of our Board of
Directors, we are pleased to welcome Jeanne and Tony to ANI. Jeanne
brings demonstrated product development and commercialization
success including extensive experience in pharmaceutical operations
and pharmaceutical supply chain experience. Her talent for process
innovation and optimization will help to guide our future growth.
Tony’s strong background in generics sales, marketing, operations
and significant product launch experience further adds to the
Board’s depth. With the addition of our new President and CEO,
Nikhil Lalwani, ANI is well positioned for future growth,” stated
Patrick D. Walsh, Chairman of the Board of Directors.
“We greatly value the feedback shared with us and are committed
to responding to the concerns raised by our stockholders during the
2020 annual meeting season, which included a commitment to
diversity on our Board,” concluded Walsh.
Ms. Thoma is currently President and CEO of SPI Pharma Inc., a
global pharmaceuticals ingredients company and an innovative
solutions provider of ingredients and drug delivery systems. During
her 30-year career, she has successfully built high-performing
businesses that are agile, innovative and consistently deliver
results. Prior to SPI, Ms. Thoma held positions of increasing
responsibility at Lonza AG, a Switzerland-based biotech company,
most recently as President and COO of the Microbial Control
Business Sector. Prior to joining Lonza, Ms. Thoma spent 14 years
at BASF Corp. in the Pharma Solutions business where she held
various leadership positions in Sales, Marketing and Operations.
Ms. Thoma is a member of the Board of Advisors for the Drug
Chemical and Associated Technologies Association (DCAT).
Mr. Pera is a seasoned pharmaceutical industry leader with 40
years of experience. He retired as President of Par Pharmaceutical,
the fifth-largest generic manufacturer in the United States, which
is now part of Endo International, plc. Prior to Par, Mr. Pera held
leadership positions at AmerisourceBergen, American Pharmaceuticals
Partners, Bedford Laboratories, a division of Ben Venue
Laboratories, and Baxter Healthcare. His breadth of experience
spans sales, marketing, supply chain operations, and licensing, and
he has played a pivotal role in the successful growth and
commercialization efforts at several successful pharma
entities.
About ANI
ANI Pharmaceuticals, Inc. is an integrated specialty
pharmaceutical company developing, manufacturing, and marketing
branded and generic prescription pharmaceuticals. The Company's
targeted areas of product development currently include narcotics,
oncolytics (anti-cancers), hormones and steroids, and complex
formulations involving extended release and combination products.
For more information, please visit our website
www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, those relating to the future growth of the Company and other
statements that are not historical in nature, particularly those
that utilize terminology such as “anticipates,” “will,” “expects,”
“plans,” “potential,” “future,” “believes,” “intends,” “continue,”
other words of similar meaning, derivations of such words and the
use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to onboarding and integrating the additions to the Board
and management team; implementing its strategic and tactical plans;
importing raw materials; competition from other products;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions, including
the ongoing impact of COVID-19; market trends; products
development; regulatory and other approvals and marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission
("SEC"), including its most recent annual report on Form 10-K and
quarterly reports on Form 10-Q, as well as other filings with the
SEC. All forward-looking statements in this news release speak only
as of the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200806005292/en/
Investor Relations: Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793 lwilson@insitecony.com
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
ANI Pharmaceuticals (NASDAQ:ANIP)
Historical Stock Chart
From Apr 2023 to Apr 2024